Navigation Links
Mindray Medical to Acquire a Controlling Stake in Suzhou Hyssen Electronics
Date:7/5/2011

SHENZHEN, China, July 5, 2011 /PRNewswire-Asia-FirstCall/ -- Mindray Medical International Limited (NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide, announced today an agreement to acquire a controlling stake of Suzhou Hyssen Electronics Co. Ltd ("Hyssen"). The terms of the agreement were not disclosed as the transaction is non-material to Mindray's financial statements.

Founded in 2003 and based in Suzhou, China, Hyssen is one of the market leaders in automated urine sediment analyzers in China. Urine sediment analysis can detect kidney and urinary tract diseases by analyzing blood cells, bacteria, urinary casts, etc., in urine samples. Urine sediment and dry chemistry analysis form urinalysis. Urinalysis, together with hematology and biochemistry analysis, are the three most common methods used in in-vitro diagnostic market. In 2010, the diagnostic urinalysis market in China was approximately $155 million, of which urine sediment analysis accounted for about 45% of the total, growing at an annual rate of over 30%.

Mindray expects to achieve synergies in the transaction by combining its strong engineering, manufacturing, sales and management platforms with Hyssen's technology and expertise in urine sediment analysis. "We are excited about this transaction and believe that our collaboration will benefit both Mindray and Hyssen," said Mr. Minghe Cheng, Mindray's Chief Strategic Officer. "Hyssen's products complement our current in-vitro diagnostic product offerings in urine dry chemistry, hematology and biochemistry. With the new additions, we believe that our in-vitro diagnostic segment can now provide our customers with better and more complete solutions."

About MindrayWe are a leading developer, manufacturer and marketer of medical devices worldwide. We maintain global headquarters in Shenzhen, China, U.S. headquarters in Mahwah, New Jersey and multiple sales offices in major international markets. From our main manufacturing and engineering base in China and through our worldwide distribution network, we are able to supply internationally a broad range of products across three primary business segments, comprised of patient monitoring and life support products, in-vitro diagnostic products and medical imaging systems. For more information, please visit http://ir.mindray.com.

Cautionary Note Regarding Forward Looking Statements

This press release contains "forward-looking statements". These statements are not historical facts but instead represent only our belief regarding future events, many of which, by their nature, are inherently uncertain and outside of our control. It is possible that our actual results achieved may differ, possibly materially, from the anticipated results indicated in these forward-looking statements. Readers are cautioned that these forward-looking statements are only predictions and may differ materially from actual future events or results due to a variety of factors, including but not limited to: our ability to close the agreed upon transaction; the size and expected growth of the diagnostic urinalysis market and the urine sediment analysis market in China and/or internationally; our ability to achieve synergies in the transaction; and the capability of our in-vitro diagnostic segment to provide our customers with better and more complete solutions. The financial information contained in this release should be read in conjunction with the consolidated financial statements and notes thereto included in our public filings with the Securities and Exchange Commission. For a discussion of other important factors that could adversely affect our business, financial condition, results of operations and prospects, see "Risk Factors" beginning on page 7 of our annual report on Form 20-F, filed on May 7, 2010. Any projections in this release are based on limited information currently available to us, which is subject to change. Although such projections and the factors influencing them will likely change, we will not necessarily update the information. Such information speaks only as of the date of this press release.For investor inquiries please contact:In the U.S:Hoki LukWestern Bridge, LLCTel: +1-646-808-9150Email: hoki.luk@westernbridgegroup.comIn China: Cathy GaoMindray Medical International LimitedTel: + 86 755 8188 8023Email: cathy.gao@mindray.com
'/>"/>

SOURCE Mindray Medical International Limited
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mindray Medical Receives the 2011 Medical Device Excellence Award for its V Series Patient Monitoring System
2. Mindray Appoints Ms. Fannie Lin Fan as General Counsel
3. Mindray Announces First Quarter 2011 Financial Results
4. Mindray Files Annual Report on Form 20-F with U.S. Securities and Exchange Commission
5. Mindray to Report First Quarter 2011 Financial Results on May 9, 2011
6. Mindray Medical to Exhibit New Products at 65th China International Medical Equipment Fair
7. Mindray Appoints Mr. Jie Liu as Chief Financial Officer
8. Mindray Medical to Present at the 14th Annual Credit Suisse Asian Investment Conference on March 21-25
9. Mindray Medical to Acquire a Controlling Stake in Shenke Medical
10. Mindray Announces 2010 Fourth Quarter and Full Year Results
11. Mindray Announces FDA 510(k) Clearance of Its A5 Anesthesia System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... SYDNEY , June 26, 2016 One of ... , has announced the formation of a new biotechnology company, Noxopharm ... raise $6m in an IPO and to list on the ASX. ... drug candidate, NOX66, ready to enter a Phase 1 clinical study ... been designed to address one of the biggest problems facing cancer ...
(Date:6/26/2016)... June 27, 2016 Jazz Pharmaceuticals plc (Nasdaq: ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as ... Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ) ... Daylight Time). As previously announced on May ... definitive merger agreement under which Jazz Pharmaceuticals has commenced ...
(Date:6/26/2016)... Ontario , June 27, 2016  VMS Rehab ... Company,s Board will take whatever measures required to build ... Company,s stock which is currently listed on the OTC ... Wexler, Company Chairman and CEO, "We are seeing an ... difficult to understand, not only by the Company, but ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... authorized OSHA Training Institute Education Center headquartered in Northern California, has issued an ... extreme heat at their worksites. Employers with workers exposed to high temperatures ...
(Date:6/27/2016)... ... 27, 2016 , ... "FCPX editors can now reveal their media with growing ... said Christina Austin - CEO of Pixel Film Studios. , ProSlice Color brings ... users can now reveal the media of their split screens with growing colorful panels. ...
(Date:6/27/2016)... ... June 27, 2016 , ... TherapySites, ... its affiliation with Tennessee Counseling Association. This new relationship allows TherapySites ... Tennessee Counseling Association, adding exclusive benefits and promotional offers. , "TCA is extremely ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... announced its strategic partnership with Connance, a healthcare industry leader providing predictive ... proven, proprietary technology combine to provide health systems, hospitals and ambulatory surgical ...
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... cutting edge technology to revolutionize the emergency ambulance transport experience for the millions ... aware of how Uber has disrupted the taxi industry through the use of ...
Breaking Medicine News(10 mins):